Plasticell leads gene therapy manufacturing consortium

26 June 2018

Privately-held UK biotech Plasticell is to lead a consortium seeking to develop advanced technologies for the manufacturing of ex vivo gene therapies.

The initial focus of the consortium of gene therapy groups at University College London’s (UCL) Institute of Child Health (ICH) and Great Ormond Street Hospital (GOSH) is on rare inherited disorders of the immune system including chronic granulomatous disease.

Yen Choo, founder and executive chairman of Plasticell, said: “There are a number of highly promising gene therapy targets currently under investigation globally but in order to commercialize these potential cures, the industry urgently needs to find better ways of manufacturing therapeutic products.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK